Richard Thomas Williams - Dec 1, 2022 Form 4 Insider Report for Kinnate Biopharma Inc. (KNTE)

Role
Chief Medical Officer
Signature
/s/ Mark A. Meltz, as attorney-in-fact
Stock symbol
KNTE
Transactions as of
Dec 1, 2022
Transactions value $
-$4,193
Form type
4
Date filed
12/2/2022, 07:00 PM
Previous filing
Sep 2, 2022
Next filing
Feb 14, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KNTE Common Stock Tax liability -$4.19K -541 -0.79% $7.75 67.9K Dec 1, 2022 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 23,438 shares represented by restricted stock units ("RSUs"). Each RSU represents the Reporting Person's right to receive one share of Common Stock of the Issuer. A portion of the RSUs vest each quarter, subject to the Reporting Person's continued service as of each vesting date.